U.S. markets closed
  • S&P 500

    3,351.60
    +53.14 (+1.61%)
     
  • Dow 30

    27,584.06
    +410.10 (+1.51%)
     
  • Nasdaq

    11,117.53
    +203.96 (+1.87%)
     
  • Russell 2000

    1,510.34
    +35.43 (+2.40%)
     
  • Crude Oil

    40.59
    -0.01 (-0.02%)
     
  • Gold

    1,885.90
    +3.60 (+0.19%)
     
  • Silver

    23.86
    +0.26 (+1.08%)
     
  • EUR/USD

    1.1671
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    0.6630
    +0.0040 (+0.61%)
     
  • GBP/USD

    1.2846
    +0.0005 (+0.04%)
     
  • USD/JPY

    105.5150
    -0.0040 (-0.00%)
     
  • BTC-USD

    10,810.77
    +31.96 (+0.30%)
     
  • CMC Crypto 200

    224.73
    +0.81 (+0.36%)
     
  • FTSE 100

    5,927.93
    +85.26 (+1.46%)
     
  • Nikkei 225

    23,511.62
    +307.00 (+1.32%)
     

Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Simply Wall St

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks with a good story, even if those businesses lose money. Unfortunately, high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson.

In contrast to all that, I prefer to spend time on companies like Bio-Techne (NASDAQ:TECH), which has not only revenues, but also profits. While profit is not necessarily a social good, it's easy to admire a business that can consistently produce it. While a well funded company may sustain losses for years, unless its owners have an endless appetite for subsidizing the customer, it will need to generate a profit eventually, or else breathe its last breath.

See our latest analysis for Bio-Techne

How Quickly Is Bio-Techne Increasing Earnings Per Share?

As one of my mentors once told me, share price follows earnings per share (EPS). That means EPS growth is considered a real positive by most successful long-term investors. Who among us would not applaud Bio-Techne's stratospheric annual EPS growth of 43%, compound, over the last three years? Growth that fast may well be fleeting, but like a lotus blooming from a murky pond, it sparks joy for the wary stock pickers.

One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. While we note Bio-Techne's EBIT margins were flat over the last year, revenue grew by a solid 3.4% to US$739m. That's a real positive.

In the chart below, you can see how the company has grown earnings, and revenue, over time. Click on the chart to see the exact numbers.

earnings-and-revenue-history
earnings-and-revenue-history

Of course the knack is to find stocks that have their best days in the future, not in the past. You could base your opinion on past performance, of course, but you may also want to check this interactive graph of professional analyst EPS forecasts for Bio-Techne.

Are Bio-Techne Insiders Aligned With All Shareholders?

Since Bio-Techne has a market capitalization of US$9.5b, we wouldn't expect insiders to hold a large percentage of shares. But we are reassured by the fact they have invested in the company. With a whopping US$54m worth of shares as a group, insiders have plenty riding on the company's success. This should keep them focused on creating long term value for shareholders.

Does Bio-Techne Deserve A Spot On Your Watchlist?

Bio-Techne's earnings have taken off like any random crypto-currency did, back in 2017. That sort of growth is nothing short of eye-catching, and the large investment held by insiders certainly brightens my view of the company. The hope is, of course, that the strong growth marks a fundamental improvement in the business economics. So yes, on this short analysis I do think it's worth considering Bio-Techne for a spot on your watchlist. You should always think about risks though. Case in point, we've spotted 1 warning sign for Bio-Techne you should be aware of.

You can invest in any company you want. But if you prefer to focus on stocks that have demonstrated insider buying, here is a list of companies with insider buying in the last three months.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.